[Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)]

Rev Med Chir Soc Med Nat Iasi. 1997 Jul-Dec;101(3-4):120-2.
[Article in Romanian]

Abstract

There are multiple lipids anomalies on diabetes. IDDM has, because of insulin lack, raised levels of triglycerides and afferent lipoproteins. NIDDM, especially the obese one, directly linked with insulin-resistance and hyperinsulinemia, has different and complex anomalies. There is a specific type named "B phenotype" with high cardiovascular risk: raised LDL chol charged with TG and low level of HDL chol. Our study on 58 cases with NIDDM obese concluded that only 28% had high TG levels but 71.8% had low levels of HDL chol. We administered fibrates, therapeutical doses, 3 months. We made lipidograms from the beginning and after one and three months. So we proved the good effect of fibrates on lipids: rise of HDL chol., moderate effect on LDL chol. for reduced cardio-vascular risk. There were good results on glucose tolerability (improving 65.8%, p < 0.01).

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Clofibric Acid / analogs & derivatives*
  • Clofibric Acid / therapeutic use
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Fenofibrate / therapeutic use*
  • Fibric Acids
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / analysis
  • Male
  • Middle Aged
  • Obesity*

Substances

  • Blood Glucose
  • Fibric Acids
  • Hypolipidemic Agents
  • Lipids
  • Clofibric Acid
  • ciprofibrate
  • Fenofibrate